COVID Vaccine (Myeloma & CLL), MANHATTAN And More

First, we review some early evidence of antibody response following COVID vaccination in patients with multiple myeloma and CLL. Then, we discuss nivolumab's approval with chemo for first-line treatment of gastric cancer (& GEJ & adenocarcinoma of the esophagus) and the MANHATTAN study and its high rate of MRD-negativity in myeloma. 5-yr OS data is published for pembrolizumab in PD-L1 > 50% NSCLC and a new drug is approved for the 1st time while recording the Pod.